Half-year report · Q2
4503.TEDINET S100UMIP
Period2024-04-01 → 2024-09-30
Filed2024-11-06
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 47
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥935.6bn | 2024-04-01 → 2024-09-30 | Cons. | Revenue IFRS |
| Revenue | ¥1.60T | 2023-04-01 → 2024-03-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥767.1bn | 2023-04-01 → 2023-09-30 | Cons. | Revenue IFRS |
| Operating income | ¥93.7bn | 2024-04-01 → 2024-09-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥55.2bn | 2023-04-01 → 2023-09-30 | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥89.0bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥25.0bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥56.3bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss before tax IFRS |
| Net income (owners) | ¥73.5bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥17.0bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥35.8bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | ¥73.5bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss IFRS |
| Net income | ¥35.8bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss IFRS |
| Total assets | ¥3.46T | at 2024-09-30 | Cons. | Assets IFRS |
| Total assets | ¥3.57T | at 2024-03-31 | Cons. | Assets IFRS |
| Total assets | ¥3.55T | at 2023-09-30 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥1.93T | at 2024-09-30 | Cons. | Liabilities IFRS |
| Total liabilities | ¥1.97T | at 2024-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥1.53T | at 2024-09-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.60T | at 2024-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.64T | at 2023-09-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.51T | at 2023-03-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥1.53T | at 2024-09-30 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥1.60T | at 2024-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥1.64T | at 2023-09-30 | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥293.0bn | at 2024-09-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥335.7bn | at 2024-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥334.0bn | at 2023-09-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥376.8bn | at 2023-03-31d | Cons. | Cash and cash equivalents IFRS |
| Operating cash flow | ¥77.4bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥172.5bn | 2023-04-01 → 2024-03-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥53.2bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | −¥55.7bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥845.8bn | 2023-04-01 → 2024-03-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥787.5bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | −¥66.3bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | ¥614.1bn | 2023-04-01 → 2024-03-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | ¥670.2bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥41.06 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥9.51 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥19.97 | 2023-04-01 → 2023-09-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (diluted) | ¥40.91 | 2024-04-01 → 2024-09-30 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥9.47 | 2023-04-01 → 2024-03-31 | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥19.9 | 2023-04-01 → 2023-09-30 | Cons. | Diluted earnings loss per share IFRS |
| Equity ratio | 44.2% | at 2024-09-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 44.7% | at 2024-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 46.3% | at 2023-09-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
All source rows · 705
| Item | Context | Value | Unit |
|---|---|---|---|
| Quarterly accounting period cover page | FilingDateInstant | Original text (Japanese)第20期中 (自 2024年４月１日 至 2024年９月30日) | |
| Company name cover page | FilingDateInstant | Original text (Japanese)アステラス製薬株式会社 | |
| Company name in english cover page | FilingDateInstant | Astellas Pharma Inc. | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)代表取締役社長 岡村 直樹 | |
| Address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)東京都中央区日本橋本町二丁目５番１号 | |
| Telephone number address of registered headquarter cover page | FilingDateInstant | 03 (3244) 3000 | |
| Name of contact person address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)グローバルビジネスソリューションズコーポレートアカウンティング グループリーダー 藤田 康博 | |
| Nearest place of contact cover page | FilingDateInstant | Original text (Japanese)東京都中央区日本橋本町二丁目５番１号 | |
| Telephone number nearest place of contact cover page | FilingDateInstant | 03 (3244) 3000 | |
| Name of contact person nearest place of contact cover page | FilingDateInstant | Original text (Japanese)グローバルビジネスソリューションズコーポレートアカウンティング グループリーダー 藤田 康博 | |
| Place for public inspection cover page (text) | FilingDateInstant | Text · Plus | |
| Edinet code | FilingDateInstant | E00920 | |
| Fund code | FilingDateInstant | － | |
| Security code | FilingDateInstant | 45030 | |
| Filer name in japanese | FilingDateInstant | Original text (Japanese)アステラス製薬株式会社 | |
| Filer name in english | FilingDateInstant | Astellas Pharma Inc. | |
| Fund name in japanese | FilingDateInstant | － | |
| Fund name in english | FilingDateInstant | － | |
| Cabinet office ordinance | FilingDateInstant | Original text (Japanese)企業内容等の開示に関する内閣府令 | |
| Document type | FilingDateInstant | Original text (Japanese)第四号の三様式 | |
| Accounting standards | FilingDateInstant | IFRS | |
| Whether consolidated financial statements are prepared | FilingDateInstant | true | |
| Industry code when consolidated financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | cte | |
| Industry code when financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | － | |
| Current fiscal year start date | FilingDateInstant | 2024-04-01 | |
| Current period end date | FilingDateInstant | 2024-09-30 | |
| Type of current period | FilingDateInstant | Q2 | |
| Current fiscal year end date | FilingDateInstant | 2025-03-31 | |
| Previous fiscal year start date | FilingDateInstant | 2023-04-01 | |
| Comparative period end date | FilingDateInstant | 2023-09-30 | |
| Previous fiscal year end date | FilingDateInstant | 2024-03-31 | |
| Next fiscal year start date | FilingDateInstant | － | |
| End date of quarterly or semi annual period of next fiscal year | FilingDateInstant | － | |
| Amendment flag | FilingDateInstant | false | |
| Identification of document subject to amendment | FilingDateInstant | － | |
| Report amendment flag | FilingDateInstant | false | |
| Xbrl amendment flag | FilingDateInstant | false | |
| Business results of group (text) | FilingDateInstant | Text · Plus | |
| Description of business (text) | FilingDateInstant | Text · Plus | |
| Business risks (text) | FilingDateInstant | Text · Plus | |
| Management analysis of financial position operating results and cash flows (text) | FilingDateInstant | Text · Plus | |
| Critical contracts for operation (text) | FilingDateInstant | Text · Plus | |
| Total number of shares (text) | FilingDateInstant | Text · Plus | |
| Issued shares total number of shares etc (text) | FilingDateInstant | Text · Plus | |
| Class issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)普通株式 | |
| Name of financial instruments exchange on which securities are listed or authorized financial instruments business association to which securities are registered | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)東京証券取引所プライム市場 | |
| Description issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | Original text (Japanese)単元株式数100株 | |
| Details of employee share option program (text) | FilingDateInstant | Text · Plus | |
| Other information on share acquisition rights (text) | FilingDateInstant | Text · Plus | |
| Exercises etc of moving strike convertible bonds etc (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |